GHK-Cu
Naturally occurring copper-binding tripeptide studied for collagen synthesis, wound healing acceleration, and broad gene-expression regulation via the proteasome system. Declines sharply with age. Available in both injectable and topical forms.
What Research Shows
Studied for collagen I/III synthesis, wound healing, MMP-mediated ECM remodelling, and antioxidant defence (SOD1 upregulation). Transcriptomic analysis shows regulation of 4,000+ human genes. Studies measure wound closure rate, hydroxyproline content, and collagen gene expression. Strong preclinical and in vitro evidence; used commercially in cosmetics.
Pros & Cons
- +Epithalon: in vitro human cell evidence for telomerase activation — rare and significant for a research peptide
- +GHK-Cu regulates 4,000+ human genes according to transcriptomic analysis — unusually broad biological activity
- +GHK-Cu available in both injectable and topical forms — accessible entry point without injections
- +Decades of research behind both compounds (Khavinson's Epithalon work since the 1980s)
- +No significant toxicity in rodent studies at high doses
- +Epithalon may normalise melatonin secretion — secondary sleep and circadian benefit
- −Epithalon's telomerase activation is demonstrated in vitro (cell cultures); robust in vivo human evidence is limited
- −Theoretical concern: activating telomerase in cells with pre-existing DNA damage could theoretically promote cancer cell survival
- −GHK-Cu topicals have significantly lower penetration than injectable — skin benefits differ in magnitude
- −Epithalon courses are short (10–20 injections) but need to be repeated; total cost accumulates
- −Long-term human safety data for Epithalon is absent in Western regulatory review contexts
- −Longevity effects are inherently difficult to measure in the short term
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary significantly.
GHK-Cu wound healing effects are measurable within 14 days in animal models. Epithalon's telomere effects are assessed at the end of a 10–20 day course in published studies. Circadian and sleep quality improvements from Epithalon are often reported within the first 5–7 days of a course by self-researchers.
What People Research This For
Practical Questions
How long is an Epithalon course and how often should it be repeated?
Published Khavinson studies use 10–20 daily subcutaneous injections as a single course. Self-researchers commonly repeat this once or twice per year. There is no established optimal frequency for humans — annual or biannual cycling is based on the schedule used in animal longevity studies, not human-specific data.
Which is better for skin: topical or injectable GHK-Cu?
For dermal effects specifically (collagen, wound healing, skin thickness), topical GHK-Cu reaches dermis-level concentrations within hours and is the most practical approach. Injectable GHK-Cu provides systemic distribution that topical cannot achieve. Many self-researchers use both: topical for skin and injectable for systemic effects. Topical products are widely available commercially without requiring peptide sourcing.
Is it safe to take Epithalon if I have a personal or family history of cancer?
This is an important consideration. Telomerase is overexpressed in approximately 90% of human cancers, as it enables cancer cells to replicate indefinitely. Activating telomerase in an individual with pre-existing cellular abnormalities carries theoretical risk. Most published Epithalon studies have not tracked oncological outcomes over long timeframes. This is a question to discuss with a healthcare professional — not a determination we can make from preclinical data alone.
Where to Buy GHK-Cu in Australia
3 Australia-accessible vendors currently stock GHK-Cu. Compare prices and availability below.